Six conversations into Season 2, Steve Labkoff and Leon Rozenblit look back at what they added up to. They revisit Raihan Faroqui on AI agents at the front desk, Greg Raiz on data over gut feel in pre-seed investing, Randi Seigel and Jared Augenstein on the state-by-state map of AI law, Travis Zack on an evidence engine that grades its own sources, Sir Peter Donnelly on genetics as nature's drug trial, and Latha Valluripalli Soorya and Erica Crawford on smart glasses in the autism evaluation. Their read: the field is moving from hype into implementation, efficiency keeps arriving before accuracy, and "AI" may be too broad a word to regulate or even to argue about.

Families who suspect autism can wait up to two years for an evaluation. Dr. Latha Valluripalli Soorya, a clinical psychologist at Rush University Medical Center and co-founder of Argus Cognitive, and Dr. Erica Crawford, Clinical Director at Autism Testing 4 Kids in Dallas–Fort Worth, join Steve Labkoff and Leon Rozenblit to discuss Neurora: smart glasses a clinician wears during a standard autism assessment, with software that measures a child's gaze, facial movement and speech. AT4K was a reimbursed site in its FDA study. They cover what the clinician gets back, the hard cases where the data helps, what the published study does and doesn't show, and why the biggest time savings so far came from report writing.

Ninety-five percent of drug targets fail, and Professor Sir Peter Donnelly thinks the reason is simple: we can't run experiments on humans. Genetics is the next best thing. People who carry natural variants in a gene show what happens when that gene is dialed up or down over a lifetime. Peter, CEO and co-founder of Genomics, joins Steve Labkoff and Leon Rozenblit to explain how his company harmonized tens of thousands of genetic studies into one resource, what genetics revealed about "good" cholesterol, why the AI agent sits on top rather than at the core, and what genetics still can't tell a drug developer.